6-K: Tolebrutinib Designated Breakthrough Therapy by the FDA for Non-relapsing Secondary Progressive Multiple Sclerosis and Duvakitug Positive Phase 2b Results Demonstrate Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease
6-K: Tolebrutinib Designated Breakthrough Therapy by the FDA for Non-relapsing Secondary Progressive Multiple Sclerosis and Duvakitug Positive Phase 2b Results Demonstrate Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease
6-K：Tolebrutinib被FDA指定为治疗非复发性继发性进展型多发性硬化症的突破性疗法，以及Duvakitug 2b期阳性结果表明其在溃疡性结肠炎和克罗恩病领域具有同类最佳的潜力
资讯热榜
更新时间